# Fremanezumab for the Prevention of Menstrually-related Migraine Attacks

> **NCT06659120** · — · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 120 (estimated)

## Conditions studied

- Menstrual Migraine

## Interventions

- **DRUG:** Fremanezumab

## Key facts

- **NCT ID:** NCT06659120
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-09
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-03-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659120, "Fremanezumab for the Prevention of Menstrually-related Migraine Attacks". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06659120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*